⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 11, 2025Journal of Dermatological TreatmentOpen Access

What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor?

Yizhang Liu Kun Hu Yongfang Duan Junchen Chen Panpan Liu Shuangyuan Zhou Mi Zhang Yehong Kuang

View Full Paper

Ask AI

Bookmark

Share

Key Points

To determine the best treatment approach after failure of IL-17A inhibitors in psoriasis.
Comparative analysis of treatment outcomes after switching therapies
Evaluation of intraclass versus interclass switching
Switching to an IL-23 inhibitor resulted in improved treatment outcomes compared to switching within IL-17A inhibitors.

Implication

Switching to an IL-23 inhibitor results in better outcomes after IL-17A inhibitor failure in psoriasis.

Abstract

An intraclass switch following IL-17A inhibitors failure yielded better treatment outcomes than a switch to guselkumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69401b262d562116f28f77fe https://doi.org/10.1080/09546634.2025.2588072

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Intraclass Switching of IL-23 Inhibitors in Psoriasis: Effectiveness, Patterns, and Predictors of Response – A Retrospective Multicenter Study in Italy2025 · 3 citations
2Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registryCohort Study · 2026 · 1 citations
3Withdrawal of biologic therapy in psoriasis and prospects of clinical response recovery2025
4Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter studyRetrospective Study · 2020 · 41 citations
5Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study2024 · 15 citations

Sequential interleukin-17 inhibitors for moderate-to-severe plaque psoriasis who have an IL-17 inhibitors failure in a resource limited country: An economic evaluation2024
Comparative analysis of persistence and remission with guselkumab <i>versus</i> secukinumab and ixekizumab in the United States2024
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)2024
Balancing safety and efficacy in photodynamic therapy for facial port-wine stains in children aged 2-7 years: a prospective controlled study of light-intensity optimizationJournal of Dermatological Treatment · 2026
5-Aminolevulinic acid-based photodynamic therapy used as a long-term management approach for refractory lichen sclerosusJournal of Dermatological Treatment · 2026

More from Journal of Dermatological Treatment

More from Central South University

More from Xiangya Hospital Central South University